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and cost comparisons, with alpha = 0.05. Multivariate regression
analyses adjusted for potential cofactors inﬂuencing descriptive
analyses: logistic for mortality, negative binomial for LOS, and
log-linear for costs. RESULTS: Severity of illness was severe/
extreme for 60.2% of 2,989,776 projected hyponatremia
patients compared to 39.7% of 2,994,724 matched non-
hyponatremia patients. Mortality among hyponatremia patients
was greater than among non-hyponatremia patients (6.8%
versus 5.6%; p < 0.0001). On average, hyponatremia was asso-
ciated with 2.6 more hospital days (8.5  10.5 versus 5.9  7.7)
and 1.5 more ICU days (6.1  8.5 versus 4.6  6.7) than
non-hyponatremia (both p < 0.0001). Average total hospital
costs were $3254 greater for hyponatremia patients than non-
hyponatremia patients ($14,317  23,251 versus $11,064 
18,325; p < 0.0001). Multivariate analyses conﬁrmed greater
mortality (Odds ratio 1.03, p < 0.0001) and LOS among
patients with hyponatremia (p < 0.0001). CONCLUSION:
Hyponatremia is associated with greater severity of illness and
risk of mortality, longer LOS, and greater hospital costs. Cor-
recting hyponatremia may be important in improving these
outcomes.
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OBJECTIVE: To determine the Hemophilia A (HA) treatment
(pdFVIII or rFVIII) with the lowest cost per quality-adjusted
life-year (QALY) inMexico.METHODS:A cost-utility study was
conducted, with an institutional perspective, in two time horizons,
30 and 50 years. The discounting rate was three percent for costs
and beneﬁts. The source of information was ameta-analysis of the
international literature validated by Mexican hematologists using
the Delphi technique. A decision tree with Bayesian approach and
a Markov chain considering the probabilities of getting infected
with Hepatitis C Virus (HCV) and Immunodeﬁciency Virus (HIV)
because of the use of a Factor VIII concentrate and the availability
of the products were performed, we also included the probabilities
of HCV and HIV infections due to the use of cryoprecipitates
because of the lack of the treatments analysed. Themodel included
the states of health: HA without infection, HA+HCV, HA+HIV,
HA+HIV+HCV and death. Due to lack of published information
and low incidence observed, the probability of getting infected
with an emergent disease (Creutzfeld-Jakob, SARS) due to the use
of FVIII treatment was not included. The results were evaluated
with incremental analysis and net beneﬁts varying the incidence of
HIV and HCV and the availability of the products. The sensitivity
analysis was one-way, two-way and probabilistic (acceptability
curves and net beneﬁts).RESULTS: Patients using rFVIII get more
beneﬁts with the lowest cost per QALY when comparing to
pdFVIII treatment (30 years-analysis: rFVIII = 16.45 QALY and
USD$50,673/QALY, pdFVIII = 11.05 QALY and USD$51,950/
QALY, ICER USD$48,066; 50 years-analysis: rFVIII = 20.79
QALY and USD$51,406/QALY, pdFVIII = 12.23 QALY and
USD$60,765/QALY, ICER USD$38,042). The sensitivity analysis
varying the incidence of HIV and HCV showed the robustness of
the base study. CONCLUSION: Recombinant Factor VIII is a
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OBJECTIVE: Immunoglobulin replacement is standard therapy
that prevents/controls infectious complications caused by
primary immunodeﬁciency disorders especially common vari-
able immunodeﬁciency and X-linked agammaglobulinemia. In
Canada, the therapy is administered intravenously (IVIg) at hos-
pital, whereas in some European countries it is administered
subcutaneously (SCIg) at home and intravenously at home/
hospital. Canadian Blood Service is considering establishing SCIg
as an alternative to IVIg. Concerns over increasing health care
costs raise questions about its cost-effectiveness. The present
study is intended to estimate cost effectiveness of SCIg against
hospital-IVIg and hypothetical home-IVIg from Canada’s public
health care payer perspective. METHODS: A Markov decision-
analytical model for hypothetical patients in 12-month therapy
was used to estimate the incremental cost-effectiveness ratio
(ICER) per quality-adjusted life year (QALY) for SCIg compared
with hospital-IVIg and home-IVIg. Serious adverse events, mor-
tality, number and severity of infections were considered.
RESULTS: SCIg dominates (greater beneﬁts at lesser costs)
hospital-IVIg and produces an incremental cost effectiveness
ratio (ICER) of CND$39,500/QALY when compared to home-
IVIg. ICER is sensitive to changes in utility of infection, hospital
charges, and infusion materials. CONCLUSION: SCIg appears
to be the most cost-effective intervention if decision makers are
willing to pay CND$39,500/QALY. Therefore, it could be gradu-
ally established as an alternative to patients who are willing and
clinically suitable to switch. Uncertainty in the available com-
parative clinical effectiveness warrants a reliable comparative
clinical study.
PSY35
PREVALENCE OF METABOLIC SYNDROME AND ITS IMPACT
ON HEALTH CARE RESOURCE UTILIZATION
Kannan H, Bolge SC
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVE: To assess the prevalence of metabolic syndrome
in ﬁve European countries and to quantify its impact on
resource utilization. METHODS: Data were from the 2006
European National Health and Wellness Survey (NHWS), a
self-administered, Internet-based study of the health care atti-
tudes, behaviors, disease states, and outcomes of a demographi-
cally representative sample of adults age 18+ across ﬁve
European countries: France, Germany, Italy, Spain, and UK.
Individuals were categorized with metabolic syndrome if they
were diagnosed with diabetes and had two or more of the fol-
lowing: hypertension, high cholesterol, or obesity (BMI > 30).
Prevalence estimates were computed using frequency weights
based on gender and age distribution of each country as
reported in the International Database of the U.S. Census
Bureau. Linear regression models were developed using
unweighted data to assess the association between metabolic
syndrome and resource utilization in the past six months.
Covariates included in the models included gender, age, marital
status, education, and country of residence (reference=UK).
RESULTS: There were 1092 respondents across the ﬁve Euro-
pean countries that were categorized as having metabolic syn-
drome. These respondents project to approximately 6.24
million individuals affected by metabolic syndrome. The preva-
lence of metabolic syndrome varied across the 5 countries
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